Biotechnology - Novartis

Filter

Current filters:

Novartis

Popular Filters

1 to 25 of 92 results

UK doctors call for approval of off-label use of Avastin for wet-AMD

UK doctors call for approval of off-label use of Avastin for wet-AMD

25-02-2015

Doctors in the UK are calling on health ministers and NHS England to intervene to make Swiss pharma giant…

AvastinBiotechnologyHealthcareLucentisNovartisOphthalmicsPricingRegulationRocheUK

Further approvals for ThromboGenics’ Jetrea

12-02-2015

Belgian biotech company ThromboGenics, which is focused on developing and commercializing innovative…

AlconArgentinaBiotechnologyIsraelJetreaNovartisOphthalmicsRegulationThromboGenics

Pfenex soars on Lucentis biosimilar deal with Hospira

Pfenex soars on Lucentis biosimilar deal with Hospira

10-02-2015

Shares of US clinical-stage biotech firm Pfenex leapt 28% to $8.85 in morning trading, after the company…

BiosimilarsBiotechnologyGenentechGlobalHospiraLicensingLucentisNovartisOphthalmicsPF582PfenexResearchRoche

Could there be a Gleevec for brain cancer?

Could there be a Gleevec for brain cancer?

10-02-2015

The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid…

BiotechnologyGleevecNeurologicalNovartisResearch

FDA approves added indication for Genentech’s Lucentis

FDA approves added indication for Genentech’s Lucentis

08-02-2015

The US Food and Drug Administration on Friday approved Swiss pharma giant Roche subsidiary Genentech’s…

BiotechnologyGenentechLucentisNovartisOphthalmicsRegulationRocheUSA

Latest approval for Novartis’ Cosentyx, from US FDA

Latest approval for Novartis’ Cosentyx, from US FDA

22-01-2015

Adding to recent marketing clearances in Japan and the European Union, the US Food and Drug Administration…

BiotechnologyCosentyxDermatologicalsNovartisRegulationUSA

Novartis’ Cosentyx gets third approval, now in Europe

19-01-2015

The European Commission (EC) has approved Swiss pharma giant Novartis’ Cosentyx (secukinumab, formerly…

BiotechnologyCosentyxDermatologicalsEuropeNovartisRegulation

Sandoz’ Neupogen biosimilar backed by FDA advisory panel

Sandoz’ Neupogen biosimilar backed by FDA advisory panel

08-01-2015

The US Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC), in a unanimous vote, recommended…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyRegulationSandozUSAZarxio

FDA staffers back approval of Novartis' biosimilar of Amgen's Neupogen

FDA staffers back approval of Novartis' biosimilar of Amgen's Neupogen

06-01-2015

In briefing papers ahead of an advisory committee meeting, agency staff at the US Food and Drug Administration…

AmgenBiosimilarsBiotechnologyImmunologicalsNeupogenNovartisRegulationUSA

First ever regulatory approval of Novartis' Cosentyx, in Japan

First ever regulatory approval of Novartis' Cosentyx, in Japan

26-12-2014

The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Swiss pharma giant Novartis’…

Anti-Arthritics/RheumaticsBiotechnologyCosentyxDermatologicalsJapanNovartisRegulation

Novartis venture fund leads $34 million financing for Annexon Bioscience

Novartis venture fund leads $34 million financing for Annexon Bioscience

17-12-2014

USA-based Annexon Bioscience says it has closed a $34 million Series A-1 to support the development of…

Annexon BioscienceANX005BiotechnologyFinancialNeurologicalNovartis

Plans unveiled for Singapore’s biologics manufacturing industry

Plans unveiled for Singapore’s biologics manufacturing industry

13-12-2014

The Singapore Workforce Development Agency (WDA), Singapore Economic Development Board (EDB) and Biopharmaceutical…

AbbVieAmgenBaxterBiotechnologyGlaxoSmithKlineLonzaNovartisProductionRocheSingapore

Sandoz demonstrates safety and efficacy of Neupogen biosimilar

Sandoz demonstrates safety and efficacy of Neupogen biosimilar

08-12-2014

Sandoz, the generics subsidiary of Swiss pharma major Novartis, has today released Phase III data that…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyResearchSandoz

Array BioPharma to regain global rights to binimetinib from Novartis

04-12-2014

Shares of US biotech firm Array BioPharma leapt 22.8% to $4.80 in after-hours trading on Wednesday, after…

Array BioPharmabinimetinibBiotechnologyGlobalLicensingNovartisOncology

Novartis’ Cosentyx wins positive opinion from EMA’s CHMP

Novartis’ Cosentyx wins positive opinion from EMA’s CHMP

21-11-2014

Swiss pharma giant Novartis this morning revealed that the European Medicines Agency’s Committee for…

BiotechnologyCosentyxDermatologicalsEuropeNovartisRegulationsecukinumab

Increased scrutiny by EU5 health authorities will encourage off-label use of Avastin for wet-AMD

06-11-2014

Cost-constrained health authorities in the EU5 (France, Germany, Italy, Spain, and the UK) are increasingly…

AvastinBiosimilarsBiotechnologyEuropeFinancialLucentisMarkets & MarketingNovartisOphthalmicsRoche

MorphoSys gets milestone from Novartis; acquires new technology

21-10-2014

German company MorphoSys says it has received a milestone payment from Novartis in connection with the…

BiotechnologyLanthio PharmalanthipeptideMergers & AcquisitionsMorphoSysNovartisOphthalmicsResearch

Eylea beats Avastin and Lucentis for visual acuity in DME patients

Eylea beats Avastin and Lucentis for visual acuity in DME patients

19-10-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer saw their shares leap 8.5% to…

AvastinBayerBiotechnologyEyleaGenentechLucentisNovartisOphthalmicsRegeneron PharmaceuticalsResearchRoche

Incyte earns $60 million milestone on European reimbursement for Jakavi

Incyte earns $60 million milestone on European reimbursement for Jakavi

02-10-2014

US biopharma company Incyte says that it has earned a $60 million milestone payment from Swiss pharma…

BiotechnologyEuropeFinancialIncyteJakafiJakaviNovartisOncologyPricing

Novartis makes investment in stem cell company Gamida Cell with option agreement

Novartis makes investment in stem cell company Gamida Cell with option agreement

19-08-2014

Swiss drug major Novartis has signed an investment and option agreement with Israeli stem cell specialist…

BiotechnologyFinancialGamida CellHematologyIsraelNovartisStem cell specialistSwitzerland

Sandoz application for biosimilar Neupogen accepted by US FDA

25-07-2014

The US Food and Drug Administration has accepted the Biologics License Application for filgrastim, which…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyRegulationSandozUSAZarzio

1 to 25 of 92 results

COMPANY SPOTLIGHT

Menarini

Back to top